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Available online 22 February 2012Rats exposed to an elevated plus maze (EPM) with four open arms display antinociception
while on the maze and hyperalgesia immediately upon removal. Little is known about the
neural mechanisms underlying EPM-induced antinociception and the subsequent hyperal-
gesia except that the antinociception is not mediated by endogenous opioids. The objective
of the present study was to test the hypothesis that endogenous cannabinoids and/or the
rostral ventromedial medulla (RVM) contributes to EPM-induced antinociception. Adminis-
tration of the CB1 receptor antagonist AM251 (1 mg/kg, i.p.) had no effect on baseline noci-
ception to formalin administration into the hindpaw or on the antinociception produced by
placing a rat on the open EPM. Likewise, inactivation of the RVM by microinjecting the
GABAA receptor agonist muscimol (10 ng/0.5 μL) had no effect on the antinociceptive effect
of placing a rat in the EPM. However, RVM inactivation blocked the hyperalgesia produced
upon removal from the EPM. Although distinct classes of RVM neurons inhibit and facilitate
nociception, the present data demonstrate that the antinociception induced by the EPM and
the subsequent hyperalgesia is mediated by distinct neural pathways.







A variety of threatening and/or stressful stimuli have been
shown to produce antinociception (Fanselow, 1991; Fardin et
al., 1984; Kelly, 1982; Terman, et al., 1984; Watkins and
Mayer, 1982). Exposure to the standard elevated plus-maze
(EPM, two enclosed and two open arms), a test originally vali-
dated to study anxiety-like behaviors in rats and mice (e.g.,
Lister, 1987; Pellow et al., 1985; Stephens et al., 1986), also
has been shown to produce antinociception (Lee and
Rodgers, 1990, 1991; Rodgers et al., 1992). This antinociceptionm (A.M. Cornélio), souzar
an).
VM, rostral ventromedial
the Elsevier OA license.was relatively mild, but persisted for up to 30 min following
removal from the EPM (Lee and Rodgers, 1990, 1991). On the
other hand, it has been shown that removal of the walls (so
all four arms of the maze are open) enhances the antinocicep-
tive effects (Cornélio and Nunes-de-Souza, 2009; Mendes-
Gomes and Nunes-de-Souza, 2005, 2009). Unlike many aver-
sive stimuli (e.g., footshock) (Terman et al., 1984) and studies
with standard EPM (Lee and Rodgers, 1990, 1991), EPM-
induced antinociception is short lived: Removing rats from
the maze causes an immediate shift from antinociception to
hyperalgesia (Cornélio et al., 2011). Little is known about then@fcfar.unesp.br (R.L. Nunes-de-Souza),
medulla; PAG, periaqueductal gray
Fig. 1 – Endogenous cannabinoids do not contribute to
EPM-induced antinociception. Time (in seconds) spent
licking the paw during the second phase (n=7/group) of the
formalin test in rats treated with vehicle or AM251 (1 mg/kg,
i.p.) and exposed to the enclosed EPM or open EPM. Although
exposing rats to the open EPM produced antinociception
compared to rats in the enclosed EPM (* denotes a significant
difference, p<0.05), administration of AM251 had no effect.
Note: animals were exposed to the enclosed EPM or open
EPM only during the second phase of the formalin test.
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or the subsequent hyperalgesia.
Previous research has shown that endogenous opioids do
not contribute to EPM-induced antinociception. This antinoci-
ception is not reversed by the opioid receptor antagonist nal-
trexone and does not produce cross-tolerance to morphine
antinociception (Cornélio and Nunes-de-Souza, 2009). Many
other transmitter systems could underlie EPM induced anti-
nociception. Endogenous cannabinoids are a likely candidate
because both cannabinoids and exposure to the EPM are asso-
ciated with anxiety (Ruehle et al., 2012) and produce antinoci-
ception (Hohmann et al., 2005; Mendes-Gomes and Nunes-de-
Souza, 2005; Pertwee, 2001).
Endogenous cannabinoids and cannabinoid receptors are
present at several levels of the pain pathway, from peripheral
sensory nerve endings to spinal cord and supraspinal centers
(Iversen, 2003). Synthetic and endogenous cannabinoids have
antinociceptive and anti-hyperalgesic effects in a variety of
animal models of acute and tonic pain when administered
orally, systemically or directly into brain or spinal cord (for re-
view see Pertwee, 2001). In addition, endocannabinoids have
been shown to contribute to some forms of stress-induced an-
algesia such as that elicited by brief and continuous electric
foot shock to rats (Hohmann et al., 2005).
The antinociceptive effects of opioids and cannabinoids
are known to be mediated in part by the nociceptive modula-
tory system that runs through the periaqueductal gray (PAG)
and rostral ventromedial medulla (RVM) (Hohmann et al.,
2005; Lane et al., 2005; Meng et al., 1998; Proudfit and
Anderson, 1975; Yaksh et al., 1977). The RVM is of particular
interest because RVM on- and off-cells (Fields et al., 1983)
have been shown to facilitate and inhibit nociception, respec-
tively (Heinricher et al., 1994; Neubert et al., 2004). These find-
ings suggest that endogenous cannabinoids could mediate
EPM-induced antinociception, and the RVM could contribute
to both antinociception and post-EPM hyperalgesia. These hy-
potheses were tested by exposing rats to the EPM following
systemic administration of the CB1 receptor antagonists
AM251 or inactivation of the RVMwith the GABAA receptor ag-
onist muscimol.2. Results
2.1. Experiment 1: endogenous cannabinoids
Systemic administration of the CB1 receptor antagonist
AM251 had no effect on baseline nociception assessed during
the first phase of the formalin test [t (26)=0.41; p>0.05]. The
average time spent licking the hindpaw following formalin
administration was similar whether rats were pretreated
with AM251 (52.9±5.5 s) or vehicle (56.4±6.4).
As reported previously (Cornélio and Nunes-de-Souza,
2009), exposure to the open EPM during the second phase of
the formalin test produced a significant antinociception com-
pared to rats in the enclosed EPM [Fig. 1; F(1,24)=52.75,
p<0.05]. This antinociception was not reversed by AM251 ad-
ministration as indicated by the lack of an interaction be-
tween rats pretreated with AM251 or vehicle (F(1,24)=0.28,
p=0.60). Although administration of AM251 did not producea statistically significant difference in the amount of time
spent licking the hindpaw compared to vehicle treated rats
(F(1,24)=2.68, p=0.11), there was a trend toward greater anti-
nociception in rats treated with AM251. Enhanced antinoci-
ception on the EPM would be consistent with the anxiogenic
effects of AM251 (Ruehle et al., 2012; Sink et al., 2010).
2.2. Experiment 2: rostral ventromedial medulla
A total of 39 rats had cannula placements in or along the bor-
der of the RVM (Fig. 2). The placements were similar whether
rats were injected with saline into the RVM and placed in
the open (N=8) or enclosed EPM (N=9), or injected with mus-
cimol and placed in the open (N=12) or enclosed EPM (N=10).
The first phase of the formalin test was assessed prior to
the RVM microinjection. Thus, the groups did not differ at
this point and there was no difference in the amount of time
spent licking the hindpaw between the saline (51.8±3.2 s)
and muscimol (47.5±4.5 s) treated groups during this phase
[t (37)=0.74; p>0.05].
Rats were placed in the EPM 15 min after saline or musci-
mol was microinjected into the RVM. Rats exposed to the
open EPM spent significantly less time licking the hindpaw
during the second phase of the formalin test compared to
rats in the enclosed EPM [F(1,35)=6.84, p<0.05]. Inactivation
of the RVM by microinjecting muscimol into the RVM had no
effect on this antinociception [F(1,35)=0.00, p>0.05; Fig. 3] in-
dicating that the RVM does not contribute to EPM-induced
antinociception.
Assessment of nociception using the hot plate test imme-
diately after removing the rat from the open EPM produced a
hot plate latency of 10.4±1.0 s (Fig. 4). Microinjection of musci-
mol into the RVM reversed this hyperalgesia as is evident by a
significant increase in hot plate latency [t (11)=2.275, p<0.05].
Closer analysis of this effect revealed a bimodal effect of mus-
cimol. Six rats injected with muscimol and removed from the
open EPM had hot plate latencies greater than 18 s and 6 had
Fig. 2 – Schematic representation of location of microinjection sites in the RVM. Black squares indicate saline or muscimol
administration into the RVM. Coronal sections are taken from the Atlas of Paxinos and Watson (2005). The number in the top
left corner refers to the distance from the interaural line.
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ferent from the eight rats receiving RVM saline, all of which
had hot plate latencies less than 15 s (Chi square=5.71,
p<0.05).
Muscimol treated rats showing antinociception on the hot
plate test also tended to be the same rats showing antinoci-
ception while on the EPM. Complete antinociception (noFig. 3 – Inactivation of the RVM had no effect on EPM-induced
antinociception. Time (in seconds) spent licking the right
hind paw during the second phase (n=8–12/group) of the
formalin test. Exposure to the open EPM produced
antinociception (* denotes a significant difference with rats
exposed to the enclosed EPM, p<0.05) that was not altered by
prior microinjection of the GABAA receptor agonist muscimol
(10 ng/0.5 μL) into the RVM.hindpaw licks) on the EPM was evident in 7 of the 12 rats trea-
ted with muscimol. This antinociception was maintained in 5
rats when removed from the open EPM and tested on the hot
plate. The lack of antinociception on the hot plate in any of
the saline pretreated rats suggests that RVM muscimol
blocked the post-maze hyperalgesia so that the antinocicep-
tion induced by the open EPM persisted. This antinociceptionFig. 4 – Inactivation of the RVM blocks post-EPM induced
hyperalgesia. Hot plate latency (n=8–12/group) of rats
previously injected with formalin into the right hindpaw and
exposed to the enclosed or open EPM for 10 min. Although
hyperalgesia was evident in rats removed from the
open-EPM, inactivation of the RVM by microinjecting
muscimol reversed the hyperalgesia (* denotes a significant
difference between muscimol and saline pretreated rats
exposed to the open EPM, p<0.05).
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treated with formalin and RVM muscimol, but not exposed
to the EPM, had a mean hot plate latency of 22.04±5.13 s and
only 2 of these rats had a hot plate latency greater than 18 s
(vs. 50% of the rats exposed to the open EPM).3. Discussion
Although the primary objective of these experiments were to
determine the neural mechanisms underlying antinocicep-
tion produced by exposure to the open EPM, neither endoge-
nous cannabinoids nor the nociceptive modulatory system
that includes the RVM appears to be involved. However, the
present data indicate that the hyperalgesia produced when
rats are removed from the EPM is mediated by the RVM.
That is, inactivation of the RVM reversed the hyperalgesia
and allowed the EPM-induced antinociception to persist.
Experiment 1 showed that blockade of cannabinoid CB1 re-
ceptors had no effect on baseline nociception or the antinoci-
ception induced by exposure of rats to the open EPM. That is,
administration of the CB1 receptor antagonist AM251 did not
alter hindpaw licking during the first phase of the formalin
test prior to exposure to the EPM. Administration of AM251
also had no effect on nociception during the second phase of
formalin test when rats were on the EPM. Antinociception,
measured as a reduction in hindpaw licking, was evident in
rats exposed to the open EPMwhether pretreated with vehicle
or AM251. The greater antinociception in rats exposed to the
open as opposed to the enclosed EPM is in agreementwith pre-
vious results (Cornélio and Nunes-de-Souza, 2009; Mendes-
Gomes and Nunes-de-Souza, 2005, 2009). The inability of
AM251 to attenuate this antinociception indicates that the
mechanism mediating EPM-induced antinociception is differ-
ent from footshock-induced antinociception which is mediat-
ed, in part, by PAG cannabinoids (Hohmann et al., 2005).
Both opioids and cannabinoids produce antinociception
in part by activation of the nociceptive modulatory system
that runs through the PAG and RVM. Given that neither opi-
oids (Cornélio and Nunes-de-Souza, 2009) nor cannabinoids
appear to contribute to EPM-induced antinociception, it
was not surprising that microinjection of muscimol to inac-
tivate the RVM did not disrupt EPM-induced antinociception.
Muscimol is a GABAA receptor agonist that has been shown
to inactivate RVM neurons (Martenson et al., 2009) and at-
tenuate PAG mediated antinociception when microinjected
into the RVM (Lane et al., 2005). In the present study, micro-
injection of muscimol had no effect on EPM-induced antino-
ciception measured with the formalin test. In contrast, the
RVM has been implicated in other forms of stress-induced
antinociception (Morgan and Fields, 1993; Watkins and
Mayer, 1982).
The antinociception produced by exposure to the open, but
not the enclosed EPM is consistent with previous studies
(Cornélio and Nunes-de-Souza, 2009; Mendes-Gomes and
Nunes-de-Souza, 2005, 2009). This antinociception appears to
be adaptive in that it reduces behavioral competition from
noxious stimuli that could disrupt appropriate defensive be-
havior (Fanselow, 1991). Although the neural mechanisms
for EPM-induced antinociception remain unknown, structuresthroughout the CNS have been implicated in stress-induced
antinociception (Butler and Finn, 2009) and could contribute.
In contrast, inactivation of the RVM reversed the hyperal-
gesia that occurs when rats are removed from the EPM
(Cornélio et al., 2011). This finding is consistent with previ-
ous studies showing that RVM on- and off-cells can facilitate
and inhibit nociception, respectively (Heinricher et al., 1994;
Neubert et al., 2004). The finding that on- and off-cells ap-
pear to be mutually inhibitory (Barbaro et al., 1989) provides
a model by which hyperalgesia can rapidly replace antinoci-
ception as the environmental situation changes. The RVM
has been shown to contribute to several forms of hyperalge-
sia such as that produced by activation of the dorsomedial
nucleus of the hypothalamus (Martenson et al., 2009), micro-
injection of low doses of neurotensin into the RVM (Neubert
et al., 2004), and neuropathic pain (Carlson et al., 2007;
Pertovaara et al., 1996).
More relevant to our data is the role of the RVM in antianal-
gesia. Cues that signal safety produce a rapid reversal of both
stress and morphine-induced antinociception (Watkins et al.,
1997; Wiertelak et al., 1992). Removing rats from the EPM and
placing them in an enclosed hot plate could provide similar
safety cues. The rapid shift from antinociception to hyperal-
gesia reported here and in our previous work (Cornélio et al.,
2011) is consistent with the rapid onset of antianalgesia.
This hyperalgesia is not caused by testing rats on the hot-
plate following administration of formalin. Hyperalgesia oc-
curs upon removal from the EPM whether rats are injected
with formalin or not, is evident in mice tested with formalin
upon removal from the EPM, and does not occur when rats
are injected with formalin and tested on the hot plate, but
not exposed to the EPM (Cornélio et al., 2011). Hyperalgesia is
not caused by a change in how nociception is assessed (i.e.,
formalin to hot-plate) because control rats did not show
hyperalgesia when tested on the hot plate, and our previous
study showed a similar enhancement of nociception when
mice were assessed with the formalin test after removal
from the maze (Cornélio et al., 2011). However, assessment
of tail-flick latency revealed a mild antinociception in mice
following exposure to the standard EPM (Lee and Rodgers,
1990, 1991). This antinociception could be caused by differ-
ences in stress induced by the open and standard EPM's or
from restraint stress when moving the mouse from the EPM
to the tail flick test.
Finally, inactivation of the RVM attenuates antianalgesia
(Watkins et al., 1998) just like muscimol inactivation of the
RVM attenuated hyperalgesia following removal from the EPM
in the present study. Removing this hyperalgesic input from
the RVM allowed the EPM-induced antinociception to persist
after the ratswere removed from the EPM. This finding suggests
that the antinociceptive and hyperalgesic effects are mediated
by distinct and competing systems. The RVM contributes to
the hyperalgesic effect, but the neural basis for EPM-induced
antinociception remains unknown. Opioid (Cornélio and
Nunes-de-Souza, 2009), cannabinoid, and descending modula-
tion from the RVMdonot appear to contribute. Thus, additional
studies are needed to investigate the role of other nociceptive
modulatory systems and transmitters. In this context, the
GABA/benzodiazepine receptor complex located within the
amygdala seems to be a strong candidate for mediation of this
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tion ofmidazolam into this limbic forebrain structure attenuat-
ed pain inhibition induced by EPM-open arm confinement in
mice (Baptista et al., 2009; Nunes-de-Souza et al., 2000).4. Experimental procedure
4.1. Subjects
Adult male Sprague–Dawley rats (213–290 g; Harlan, Kent WA,
USA) were housed in pairs in a polycarbonate cage
(33×21×20 cm) under a reverse light/dark schedule (lights off
at 07:00) in a temperature-controlled environment (22 °C).
Food and water were freely available except during the brief
test period. Rats were handled daily for at least 4 days prior
to the beginning of the experiment to reduce stress associated
with handling. All animals were experimentally naïve and all
testing was conducted during the dark phase when rats are
awake and active. Rats were transported to the dimly light ex-
perimental room and left undisturbed for at least 1 h prior to
testing. Testing was conducted between 10:00 and 16:00. All
procedures were conducted in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and approved by the Institutional Animal Care and
Use Committee at Washington State University. Efforts were
made to minimize the number and potential suffering of
subjects.
4.2. Drugs
The CB1 receptor antagonist AM 251 [(N-(Piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-
carboxamide); Tocris Cookson Inc., USA], was dissolved in 60%
DMSO and saline (Wilson et al., 2008). The GABAA receptor ag-
onist muscimol (Sigma-Aldrich; St. Louis, MO, USA) was dis-
solved in saline. AM251 (1 mg/kg, i.p.) and muscimol (10 ng/
0.5 μL) doses and concentrations were selected based on pre-
vious studies (Lane et al., 2005; Wilson et al., 2008).
4.3. Enclosed and open elevated plus maze
The enclosed and open EPM are modifications of the standard
elevated plus maze previously described (Pellow et al., 1985).
They consist of four arms (50×10 cm) connected to a common
central platform (10×10 cm) covered in gray plastic. All four
walls were either enclosed with Plexiglas (40 cm high) or
open except for a 0.25 cm high edge. The arms of the maze
were 50 cm above floor level.
4.4. Nociceptive tests
Nociception was assessed using the formalin and hot plate
tests. The formalin test consists of injecting 50 μL of formalin
(2.5% formaldehyde) into the plantar surface of the right hind
paw and measuring the amount of time spent licking the paw
over two phases of responding (Abbott et al., 1999; Dubuisson
and Dennis, 1977). The first phase begins immediately follow-
ing formalin injection and lasts approximately 5 min. Rats
were placed in a clear Plexiglas cage to record the amount oftime spent licking the hind paw during the first phase. The
second phase begins approximately 20 min after the formalin
injection and lasts approximately 40 min (Bon et al., 2002).
The amount of time spent licking the hind paw during the
second phase of the formalin test was evaluated for 10 min
(25–35 min after formalin injection) while rats were on the
enclosed or open EPM.
The hot plate test was used to assess nociception immedi-
ately following exposure to the EPM. This test consists of plac-
ing a rat on an enclosed square plate heated to 52.5 °C. The
latency for the rat to lick a hind paw was measured. Rats
were removed from the hot plate if no response occurred
within 50 s.
4.5. Procedure
4.5.1. Experiment 1: role of endogenous cannabinoids
The objective of this experiment was to test the hypothesis
that endogenous cannabinoids contribute to antinociception
produced by exposure to the open EPM. Rats (n=7/group)
were treated with vehicle or the CB1 receptor antagonist
AM251 (1 mg/kg, i.p.). This dose was selected based on its abil-
ity to block cannabinoid effects in our previous study (Wilson
et al., 2008). Fifteen minutes later, formalin was injected into
the plantar surface of the right hind paw. Twenty-five mi-
nutes after formalin injection, rats were placed in the
enclosed or open EPM for 10 min and nociception was
assessed by measuring the time spent licking the paw.
4.5.2. Experiment 2: role of the RVM in EPM-induced
antinociception
The objective of this experiment was to test the hypothesis
that the nociceptive modulatory system that includes the
RVM contributes to antinociception produced by exposure to
the open EPM. Rats were anesthetized with equithesin
(60 mg/kg, i.p.) and stereotaxically implanted with a 23-
gauge stainless steel guide cannula (13 mm long) aimed at
the RVM (anterior: −2.3 mm; ventral: −7.9 mm; lateral: 0 mm
from lambda) (Paxinos and Watson, 2005). The guide cannula
was held in place with dental cement affixed to two screws in
the skull. Following surgery, a removable stainless steel stylet
was inserted into the guide cannula. No postoperative medi-
cation was administered to avoid possible cross-tolerance to
environment-induced antinociception. Rats were housed in-
dividually for 1 day following surgery before being returned
to a cage with two rats.
Rats were allowed to recover for 5–8 days prior to testing.
One day before testing, each animal received a sham injec-
tion, in which an injector (31 gauge) extending 2 mm beyond
the tip of a 13 mm guide cannula was inserted into the guide
cannula but no drug was administered. This procedure habit-
uates the rat to the microinjection procedure and reduces
confounds resulting from mechanical damage to neurons on
the test day.
On the test day, formalin was injected into the right hind
paw, and the time spent licking the paw was recorded for
5 min while the rat was in a Plexiglas cage. Ten minutes
after formalin administration saline or muscimol (10 ng/
0.5 μL) wasmicroinjected into the RVM using an injection can-
nula that extended 2 mmbeyond the guide cannula. This dose
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shown previously (Lane et al., 2005; Martenson et al., 2009).
The injection cannula was connected to a 1 μL syringe (Hamil-
ton Co., Reno, NV) via PE20 tubing filled with sterile water.
Drugs were administered in a volume of 0.5 μL at a rate of
0.5 μL/60 s while the rat was gently restrained by hand. The in-
jection cannula remained in place an additional 40 s to mini-
mize backflow of the drug up the cannula track. The stylet
was replaced following the injection.
Animals were exposed to the enclosed or open EPM 15 min
after the microinjection, and the time spent licking the paw
was measured for 10 min. Immediately after exposure to the
EPM, rats were tested on the hot plate. A control group (n=7)
injected with formalin in the hind paw and muscimol in the
RVM, but not placed in the EPMwas included to assess wheth-
er these factors influence hot plate latency independent of the
EPM. At the end of the experiment rats were given a lethal
dose of Halothane and their brains were removed and placed
in formalin. At least two days later, 100 μm coronal sections
were made and the location of the injection site was plotted
on an atlas (Paxinos and Watson, 2005). Data from animals
with injection sites outside the RVM were not included in
data analysis.
4.6. Statistics
Data were initially submitted to a test of homogeneity of var-
iances. Groups were compared by submitting data to analysis
of variance (ANOVA) or t-test. Data from the first phase of the
formalin test were analyzed by t-test for independent sam-
ples. Data from the second phase of the formalin test were
submitted to two-way ANOVA (factor 1: type of maze; factor
2: treatment). Hot plate data were analyzed by t-test for inde-
pendent samples. Chi squared was used to analyze the num-
ber of rats displaying antinociception. In all cases, a p
value≤0.05 was required for significance.Acknowledgments
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